Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Current promising treatment strategy for glioblastoma multiform: A review.

Bahadur S, Sahu AK, Baghel P, Saha S.

Oncol Rev. 2019 Jul 25;13(2):417. doi: 10.4081/oncol.2019.417. eCollection 2019 Jul 22.

2.

Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.

Yang B, Ma YB, Chu SH.

Cancer Gene Ther. 2018 Dec;25(11-12):309-316. doi: 10.1038/s41417-018-0040-3. Epub 2018 Aug 24.

PMID:
30140041
3.

Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability.

St-Coeur PD, Cormier M, LeBlanc VC, Morin PJ, Touaibia M.

Med Chem. 2016;13(1):28-39. doi: 10.2174/1573406412666160710210907.

PMID:
27396904
4.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

5.

Temozolomide: mechanisms of action, repair and resistance.

Zhang J, Stevens MF, Bradshaw TD.

Curr Mol Pharmacol. 2012 Jan;5(1):102-14.

PMID:
22122467
6.

The strategy for enhancing temozolomide against malignant glioma.

Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J.

Front Oncol. 2012 Aug 14;2:98. doi: 10.3389/fonc.2012.00098. eCollection 2012.

7.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

8.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
9.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

10.

Temozolomide resistance in glioblastoma multiforme.

Lee SY.

Genes Dis. 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. eCollection 2016 Sep. Review.

11.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguro─člu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
12.

Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Viel T, Monfared P, Schelhaas S, Fricke IB, Kuhlmann MT, Fraefel C, Jacobs AH.

Mol Ther. 2013 Mar;21(3):570-9. doi: 10.1038/mt.2012.278. Epub 2013 Jan 15.

13.

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.

Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.

Clin Transl Oncol. 2018 Apr;20(4):508-516. doi: 10.1007/s12094-017-1743-x. Epub 2017 Aug 20.

PMID:
28825189
14.

O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.

Int J Mol Sci. 2012;13(6):6983-94. doi: 10.3390/ijms13066983. Epub 2012 Jun 7.

15.

Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.

Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y.

Jpn J Clin Oncol. 2007 Dec;37(12):897-906. Epub 2007 Dec 21.

PMID:
18156172
16.

GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.

Wang HH, Chang TY, Lin WC, Wei KC, Shin JW.

Sci Rep. 2017 Aug 18;7(1):8814. doi: 10.1038/s41598-017-06851-3.

17.

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.

Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.

BMC Cancer. 2014 Jan 13;14:17. doi: 10.1186/1471-2407-14-17.

18.

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.

Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, Nakamizo A, Sasaki T.

Front Oncol. 2012 Dec 5;2:186. doi: 10.3389/fonc.2012.00186. eCollection 2012.

19.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

20.

MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3╬▓ in glioblastoma.

Tian T, Mingyi M, Qiu X, Qiu Y.

Oncotarget. 2016 Nov 29;7(48):79584-79595. doi: 10.18632/oncotarget.12861.

Supplemental Content

Support Center